November 01, 2018
1 min read
Save

Sodium bicarbonate treatment achieves improvements in endothelial function in stage 3b and 4 CKD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In patients with stage 3b or stage 4 chronic kidney disease, the use of sodium bicarbonate to treat metabolic acidosis yielded significantly improved endothelial function, according to recent findings.

In the pilot, prospective, open-label 14-week crossover study, researchers assessed 20 patients with eGFR of 15 ml/min per 1.73 m2 to 44 ml/min per 1.73 m2 and low serum bicarbonate levels (16 mEq/L to 21 mEq/L). Each study interval continued for 6 weeks, with a 2-week washout period in between this time. Treatment continued to a target serum bicarbonate of at least 23 mEq/L.

Researchers found that of the 18 patients who completed the study and were included in the primary efficacy analysis, a significant increase was seen in sodium bicarbonate treatment with sodium bicarbonate treatment (+2.7±2.9 mEq/L), while no change in serum bicarbonate was observed during the control interval (-0.06±2.44 mEq/L) A total of eight patients achieved the target of at least 23 mEq/L at the end of 6 weeks. Four of these eight patients achieved the goal by week 2.
Similarly, sodium bicarbonate yielded a significant improvement in FMD after 6 weeks (mean ±SD FMD at baseline: 4.1%±4.1% mean ±SD FMD at 6 weeks: 5.2%±2.9%), while the control group did not show an improvement in FMD (mean ±SD FMD at baseline: 4.6%±3.1%: mean ±SD FMD at 6 weeks: 4.1%±3.4%). Compared with the control group, patients treated with sodium bicarbonate achieved a significant increase in FMD (mean: 1.8%). Endothelium-independent vasodilation was not affected by sodium bicarbonate treatment (mean ±SD from baseline, -0.05 %±5.5). Similarly, sodium bicarbonate treatment did not yield any significant changes in serum hs-CRP, IL-6 or calcium.

A significant increase was seen in serum phosphorus and intact fibroblast growth factor-23 during treatment. –by Jennifer Byrne